Literature DB >> 18077410

Structural insight into distinct mechanisms of protease inhibition by antibodies.

Yan Wu1, Charles Eigenbrot, Wei-Ching Liang, Scott Stawicki, Steven Shia, Bin Fan, Rajkumar Ganesan, Michael T Lipari, Daniel Kirchhofer.   

Abstract

To better understand how the relatively flat antigen-combining sites of antibodies interact with the concave shaped substrate-binding clefts of proteases, we determined the structures of two antibodies in complex with the trypsin-like hepatocyte growth-factor activator (HGFA). The two inhibitory antibodies, Ab58 and Ab75, were generated from a human Fab phage display library with synthetic diversity in the three complementarity determining regions (H1, H2, and H3) of the heavy chain, mimicking the natural diversity of the human Ig repertoire. Biochemical studies and the structures of the Fab58:HGFA (3.5-A resolution) and the Fab75:HGFA (2.2-A resolution) complexes revealed that Ab58 obstructed substrate access to the active site, whereas Ab75 allosterically inhibited substrate hydrolysis. In both cases, the antibodies interacted with the same protruding element (99-loop), which forms part of the substrate-binding cleft. Ab58 inserted its H1 and H2 loops in the cleft to occupy important substrate interaction sites (S3 and S2). In contrast, Ab75 bound at the backside of the cleft to a region corresponding to thrombin exosite II, which is known to interact with allosteric effector molecules. In agreement with the structural analysis, binding assays with active site inhibitors and enzymatic assays showed that Ab58 is a competitive inhibitor, and Ab75 is a partial competitive inhibitor. These results provide structural insight into antibody-mediated protease inhibition. They suggest that unlike canonical inhibitors, antibodies may preferentially target protruding loops at the rim of the substrate-binding cleft to interfere with the catalytic machinery of proteases without requiring long insertion loops.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077410      PMCID: PMC2148376          DOI: 10.1073/pnas.0708251104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa.

Authors:  M S Dennis; M Roberge; C Quan; R A Lazarus
Journal:  Biochemistry       Date:  2001-08-14       Impact factor: 3.162

2.  High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.

Authors:  Chingwei V Lee; Wei-Ching Liang; Mark S Dennis; Charles Eigenbrot; Sachdev S Sidhu; Germaine Fuh
Journal:  J Mol Biol       Date:  2004-07-23       Impact factor: 5.469

3.  Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.

Authors:  Steven Shia; Jennifer Stamos; Daniel Kirchhofer; Bin Fan; Judy Wu; Raquel T Corpuz; Lydia Santell; Robert A Lazarus; Charles Eigenbrot
Journal:  J Mol Biol       Date:  2005-01-28       Impact factor: 5.469

4.  Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.

Authors:  M Lauwereys; M Arbabi Ghahroudi; A Desmyter; J Kinne; W Hölzer; E De Genst; L Wyns; S Muyldermans
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

5.  Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors.

Authors:  J F Morrison
Journal:  Biochim Biophys Acta       Date:  1969

6.  Regeneration of injured intestinal mucosa is impaired in hepatocyte growth factor activator-deficient mice.

Authors:  Hiroshi Itoh; Seiji Naganuma; Naoki Takeda; Shiro Miyata; Shunro Uchinokura; Tsuyoshi Fukushima; Shuichiro Uchiyama; Hiroyuki Tanaka; Koki Nagaike; Takeshi Shimomura; Keiji Miyazawa; Gen Yamada; Naomi Kitamura; Masashi Koono; Hiroaki Kataoka
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.

Authors:  Jian-Ai Xuan; Doug Schneider; Pam Toy; Rick Lin; Alicia Newton; Ying Zhu; Silke Finster; David Vogel; Bob Mintzer; Harald Dinter; David Light; Renate Parry; Mark Polokoff; Marc Whitlow; Qingyu Wu; Gordon Parry
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo.

Authors:  Shunro Uchinokura; Shiro Miyata; Tsuyoshi Fukushima; Hiroshi Itoh; Shinichi Nakano; Shinichiro Wakisaka; Hiroaki Kataoka
Journal:  Int J Cancer       Date:  2006-02-01       Impact factor: 7.396

9.  Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator.

Authors:  Esther P M Tjin; Patrick W B Derksen; Hiroaki Kataoka; Marcel Spaargaren; Steven T Pals
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

10.  Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin.

Authors:  Wei Li; Daniel J D Johnson; Charles T Esmon; James A Huntington
Journal:  Nat Struct Mol Biol       Date:  2004-08-15       Impact factor: 15.369

View more
  30 in total

1.  Inhibiting alternative pathway complement activation by targeting the factor D exosite.

Authors:  Kenneth J Katschke; Ping Wu; Rajkumar Ganesan; Robert F Kelley; Mary A Mathieu; Philip E Hass; Jeremy Murray; Daniel Kirchhofer; Christian Wiesmann; Menno van Lookeren Campagne
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

2.  Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site.

Authors:  Henry R Maun; Xiaohui Wen; Andreas Lingel; Frederic J de Sauvage; Robert A Lazarus; Suzie J Scales; Sarah G Hymowitz
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 3.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

4.  Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.

Authors:  Kenneth J Katschke; Scott Stawicki; Jianping Yin; Micah Steffek; Hongkang Xi; Lizette Sturgeon; Philip E Hass; Kelly M Loyet; Laura Deforge; Yan Wu; Menno van Lookeren Campagne; Christian Wiesmann
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

5.  Functional selection of protease inhibitory antibodies.

Authors:  Tyler Lopez; Zahid Mustafa; Chuan Chen; Ki Baek Lee; Aaron Ramirez; Chris Benitez; Xin Luo; Ru-Rong Ji; Xin Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-30       Impact factor: 11.205

6.  Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition.

Authors:  Christopher J Farady; Pascal F Egea; Eric L Schneider; Molly R Darragh; Charles S Craik
Journal:  J Mol Biol       Date:  2008-05-11       Impact factor: 5.469

7.  Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.

Authors:  Dong Hyun Nam; Kuili Fang; Carlos Rodriguez; Tyler Lopez; Xin Ge
Journal:  Protein Eng Des Sel       Date:  2016-12-15       Impact factor: 1.650

Review 8.  Mechanisms of macromolecular protease inhibitors.

Authors:  Christopher J Farady; Charles S Craik
Journal:  Chembiochem       Date:  2010-11-22       Impact factor: 3.164

9.  A reverse binding motif that contributes to specific protease inhibition by antibodies.

Authors:  Eric L Schneider; Melody S Lee; Aida Baharuddin; David H Goetz; Christopher J Farady; Mick Ward; Cheng-I Wang; Charles S Craik
Journal:  J Mol Biol       Date:  2011-11-27       Impact factor: 5.469

10.  Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries.

Authors:  Dong Hyun Nam; Carlos Rodriguez; Albert G Remacle; Alex Y Strongin; Xin Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.